FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Yale Mitchel

Research Profile

Chemicals & Drugs

Procedures

Disorders

Concepts & Ideas

Co-author Network

Publications

TOP 3
Michael Davidson; Antonio M Gotto; Elizabeth T Leary; Sherry Xueyu Liu; Yale B Mitchel; Sukrut Shah; Michael Stepanavage; Philip Barter; Eliot A Brinton; Christopher P Cannon; Hayes M Dansky
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib.
Darbie Maccubbin; Christine McCrary Sisk; Anders G Olsson; Waheeda Sirah; Jennifer Weimer Anderson; Harold E Bays; Fabian Chen; Uma Kher; Yale B Mitchel
Effectiveness and safety of laropiprant on niacin-induced flushing.
Christie Ballantyne; Gilbert Gleim; Amy O Johnson-Levonas; Nancy Liu; Christine McCrary Sisk; Yale B Mitchel
Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Yale Mitchel (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Michael Davidson; Antonio M Gotto; Elizabeth T Leary; Sherry Xueyu Liu; Yale B Mitchel; Sukrut Shah; Michael Stepanavage; Philip Barter; Eliot A Brinton; Christopher P Cannon; Hayes M Dansky
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib.
Journal of lipid research 2013;54(2):467-72.
2012: Darbie Maccubbin; Christine McCrary Sisk; Anders G Olsson; Waheeda Sirah; Jennifer Weimer Anderson; Harold E Bays; Fabian Chen; Uma Kher; Yale B Mitchel
Effectiveness and safety of laropiprant on niacin-induced flushing.
The American journal of cardiology 2012;110(6):817-22.
2012: Christie Ballantyne; Gilbert Gleim; Amy O Johnson-Levonas; Nancy Liu; Christine McCrary Sisk; Yale B Mitchel
Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia.
Journal of clinical lipidology 2012;6(3):235-43.
2011: Hayes M Dansky; Patrice Gibbons; Thomas W Littlejohn; Sherry Liu; James M McKenney; Christine McCrary Sisk; Diane Tribble; Daniel Bloomfield; Yale B Mitchel
Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia.
American heart journal 2011;162(4):708-16.
2010: Menno Vergeer; Rong Zhou; Michiel L Bots; Raphaël Duivenvoorden; Joerg Koglin; Fatima Akdim; Yale B Mitchel; Roeland Huijgen; Aditi Sapre; Eric de Groot; Eric J G Sijbrands; Richard C Pasternak; Claude Gagné; A David Marais; Christie M Ballantyne; Jonathan L Isaacsohn; Anton F Stalenhoef; John J P Kastelein
Carotid atherosclerosis progression in familial hypercholesterolemia patients: a pooled analysis of the ASAP, ENHANCE, RADIANCE 1, and CAPTIVATE studies.
Circulation. Cardiovascular imaging 2010;3(4):398-404.
2009: Lawrence Gould; Joerg Koglin; Raymond P Bain; Cathy-Anne Pinto; Yale B Mitchel; Richard C Pasternak; Aditi Sapre
Effects of sources of variability on sample sizes required for RCTs, applied to trials of lipid-altering therapies on carotid artery intima-media thickness.
Clinical trials (London, England) 2009;6(4):305-19.
2009: Darbie Maccubbin; Michael J Koren; Michael Davidson; Dov Gavish; Richard C Pasternak; Geraldine Macdonell; Madhuja Mallick; Christine McCrary Sisk; John F Paolini; Yale B Mitchel
Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
The American journal of cardiology 2009;104(1):74-81.
2009: Daniel Bloomfield; Gary L Carlson; Aditi Sapre; Diane L Tribble; James M McKenney; Thomas W Littlejohn; Christine McCrary Sisk; Yale B Mitchel; Richard C Pasternak
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
American heart journal 2009;157(2):352-360.e2.
2009: Harold E Bays; Darbie Maccubbin; Alan G Meehan; Olga Kuznetsova; Yale B Mitchel; John F Paolini
Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients.
Clinical therapeutics 2009;31(1):115-22.
2008: D Maccubbin; Harold E Bays; A G Olsson; V Elinoff; A Elis; Yale B Mitchel; W Sirah; A Betteridge; R Reyes; Q Yu; O Kuznetsova; C McCrary Sisk; R C Pasternak; John F Paolini
Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
International journal of clinical practice 2008;62(12):1959-70.
2008: Michel Farnier; Inna Perevozskaya; William V Taggart; Debra Kush; Yale B Mitchel
VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate.
Journal of lipid research 2008;49(12):2641-7.
2008: John F Paolini; Harold E Bays; Christie M Ballantyne; Michael Davidson; Richard Pasternak; Darbie Maccubbin; Josephine M Norquist; Eseng Lai; M Gerard Waters; Olga Kuznetsova; Christine McCrary Sisk; Yale B Mitchel
Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.
Cardiology clinics 2008;26(4):547-60.
2008: John F Paolini; Yale B Mitchel; R Reyes; S Thompson-Bell; Q Yu; Eseng Lai; Douglas J Watson; Josephine M Norquist; C McCrary Sisk; Harold E Bays
Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial.
International journal of clinical practice 2008;62(6):896-904.
2008: John F Paolini; Yale B Mitchel; Robert Reyes; Uma Kher; Eseng Lai; Douglas J Watson; Josephine M Norquist; Alan G Meehan; Harold E Bays; Michael Davidson; Christie M Ballantyne
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
The American journal of cardiology 2008;101(5):625-30.
2007: Michel Farnier; Eli Roth; Blas Gil-Extremera; Gustavo F Mendez; Geraldine Macdonell; Constance Hamlin; Inna Perevozskaya; Michael J Davies; Debra Kush; Yale B Mitchel
Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia.
American heart journal 2007;153(2):335.e1-8.
2007: Theodore Feldman; Leiv Ose; Arvind Shah; Michelle Zakson; Alan Meehan; Amy O Johnson-Levonas; Darbie Maccubbin; Diane L Tribble; Enrico Veltri; Yale B Mitchel
Efficacy and safety of ezetimibe/simvastatin versus simvastatin monotherapy in hypercholesterolemic patients with metabolic syndrome.
Metabolic syndrome and related disorders 2007;5(1):13-21.
2006: Theodore Feldman; Michael Davidson; Arvind Shah; Darbie Maccubbin; Alan Meehan; Michelle Zakson; Diane L Tribble; Enrico Veltri; Yale B Mitchel
Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
Clinical therapeutics 2006;28(6):849-59.
2006: Leiv Ose; Arvind Shah; Michael J Davies; Jennifer Rotonda; Darbie Maccubbin; Diane L Tribble; Enrico Veltri; Yale B Mitchel
Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
Current medical research and opinion 2006;22(5):823-35.
2006: James M McKenney; Michel Farnier; Kwok-Wing Lo; Harold E Bays; Inna Perevozkaya; Gary Carlson; Michael J Davies; Yale B Mitchel; Barry Gumbiner
Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.
Journal of the American College of Cardiology 2006;47(8):1584-7.
2005: Michel Farnier; Mason W Freeman; Geraldine Macdonell; Inna Perevozskaya; Michael J Davies; Yale B Mitchel; Barry Gumbiner
Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.
European heart journal 2005;26(9):897-905.
2005: Philip T Sager; Rachel Capece; Leslie Lipka; John Strony; Bo Yang; Ramachandran Suresh; Yale B Mitchel; Enrico Veltri
Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients.
Atherosclerosis 2005;179(2):361-7.
2005: Yale B Mitchel
High-dose statins in acute coronary syndromes.
JAMA : the journal of the American Medical Association 2005;293(1):37; author reply 38-9.
2005: James McKenney; Christie M Ballantyne; Theodore A Feldman; William E Brady; Arvind Shah; Michael J Davies; Joanne Palmisano; Yale B Mitchel
LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD.
MedGenMed : Medscape general medicine 2005;7(3):3.
2005: L M Gaudiani; A Lewin; Luigi F Meneghini; I Perevozskaya; Diane J Plotkin; Yale B Mitchel; S Shah
Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients.
Diabetes, obesity & metabolism 2005;7(1):88-97.
2004: Kalevi Pyörälä; Christie M Ballantyne; Barry Gumbiner; Michael W Lee; Arvind Shah; Michael J Davies; Yale B Mitchel; Terje R Pedersen; John Kjekshus
Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S).
Diabetes care 2004;27(7):1735-40.
2004: Theodore Feldman; Michael J Koren; William Insull; James McKenney; Helmut Schrott; Andrew Lewin; Sukrut Shah; Michelle Sidisin; Meehyung Cho; Debra Kush; Yale B Mitchel
Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals.
The American journal of cardiology 2004;93(12):1481-6.
2004: Anne C Goldberg; Aditi Sapre; Ji Liu; Rachel Capece; Yale B Mitchel
Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial.
Mayo Clinic proceedings. Mayo Clinic 2004;79(5):620-9.
2004: Andrew J Lewin; Mark S Kipnes; Luigi F Meneghini; Diane J Plotkin; Inna Perevozskaya; Sukrut Shah; Darbie Maccubbin; Yale B Mitchel; Jonathan A Tobert
Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.
Clinical therapeutics 2004;26(3):379-89.
2003: Donald B Hunninghake; Christie M Ballantyne; Darbie Maccubbin; Arvind K Shah; Barry Gumbiner; Yale B Mitchel
Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome.
Clinical therapeutics 2003;25(6):1670-86.
2003: Jonathan L Isaacsohn; Donald B Hunninghake; Helmut Schrott; Carlos A Dujovne; Robert Knopp; Stuart R Weiss; Harold E Bays; John R Crouse; Michael H Davidson; Leonard M Keilson; James McKenney; Stanley G Korenman; Adrian S Dobs; Evan Stein; Ronald M Krauss; Darbie Maccubbin; Meehyung Cho; Diane J Plotkin; Yale B Mitchel
Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia.
Clinical cardiology 2003;26(1):18-24.
2002: Harold E Bays; Evan A Stein; Arvind K Shah; Darbie Maccubbin; Yale B Mitchel; Michele Mercuri
Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients.
The American journal of cardiology 2002;90(9):942-6.
2002: Diane J Plotkin; Sam Miller; Steven Nakajima; Edward Peskin; Ronald T Burkman; David Richardson; Yale B Mitchel; Joanne Waldstreicher; Minzhi Liu; Deborah Shapiro; Nanette Santoro
Lowering low density lipoprotein cholesterol with simvastatin, a hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, does not affect luteal function in premenopausal women.
The Journal of clinical endocrinology and metabolism 2002;87(7):3155-61.
2001: D Roger Illingworth; John R Crouse; Donald B Hunninghake; Michael H Davidson; Ivan D Escobar; A F Stalenhoef; G Paragh; P T Ma; Mingyue Liu; MR Melino; L O'Grady; Michele Mercuri; Yale B Mitchel
A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
Current medical research and opinion 2001;17(1):43-50.
2000: Michael H Davidson; Evan A Stein; Donald B Hunninghake; Leiv Ose; Carlos A Dujovne; William Insull; Marcelo C Bertolami; Stuart R Weiss; John J P Kastelein; Russell S Scott; S Campodónico; Ivan D Escobar; Helmut Schrott; Harold E Bays; Michael Stepanavage; M Wu; A C Tate; MR Melino; Debra Kush; Michele Mercuri; Yale B Mitchel
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia.
Nutrition, metabolism, and cardiovascular diseases : NMCD 2000;10(5):253-62.
2000: Adrian S Dobs; Helmut Schrott; Michael H Davidson; Harold E Bays; Evan A Stein; Debra Kush; M Wu; Yale B Mitchel; R D Illingworth
Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia.
Metabolism: clinical and experimental 2000;49(9):1234-8.
2000: Joseph A Vita; A C Yeung; M Winniford; J M Hodgson; C B Treasure; J L Klein; S Werns; M Kern; Diane J Plotkin; W J Shih; Yale B Mitchel; Peter Ganz
Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease.
Circulation 2000;102(8):846-51.
2000: John J P Kastelein; Jonathan L Isaacsohn; Leiv Ose; Donald B Hunninghake; J Frohlich; Michael H Davidson; R Habib; Carlos A Dujovne; John R Crouse; M Liu; MR Melino; L O'Grady; Michele Mercuri; Yale B Mitchel
Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels.
The American journal of cardiology 2000;86(2):221-3.
2000: Leiv Ose; Michael H Davidson; Evan A Stein; John J P Kastelein; Russell S Scott; Donald B Hunninghake; S Campodonico; William Insull; Ivan D Escobar; Helmut Schrott; Michael Stepanavage; M Wu; A C Tate; MR Melino; Michele Mercuri; Yale B Mitchel
Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group.
Clinical cardiology 2000;23(1):39-46.
1998: Evan A Stein; Michael H Davidson; Adrian S Dobs; Helmut Schrott; Carlos A Dujovne; Harold E Bays; Stuart R Weiss; MR Melino; Michael Stepanavage; Yale B Mitchel
Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group.
The American journal of cardiology 1998;82(3):311-6.
1997: Frederick J Raal; GJ Pilcher; D Roger Illingworth; Anuradha S Pappu; Evan A Stein; PM Laskarzewski; Yale B Mitchel; MR Melino
Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia.
Atherosclerosis 1997;135(2):249-56.
1997: Michael H Davidson; Evan A Stein; Carlos A Dujovne; Donald B Hunninghake; Stuart R Weiss; Robert H Knopp; D Roger Illingworth; Yale B Mitchel; MR Melino; R V Zupkis; MR Dobrinska; R D Amin; Jonathan A Tobert
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day.
The American journal of cardiology 1997;79(1):38-42.
1994: D Roger Illingworth; Evan A Stein; Yale B Mitchel; Carlos A Dujovne; P H Frost; R H Knopp; P Tun; R V Zupkis; R A Greguski
Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial.
Archives of internal medicine 1994;154(14):1586-95.
1993: H Cheng; S C Sutton; J D Pipkin; G M Zentner; John D Rogers; Jules I Schwartz; Yale B Mitchel; K Grasing; M S Schwartz; RD Amin
Evaluation of sustained/controlled-release dosage forms of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors in dogs and humans.
Pharmaceutical research 1993;10(11):1683-7.
1992: G A Block; Yale B Mitchel; Jonathan A Tobert; D R Shapiro
Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance.
Clinical cardiology 1992;15(10):A24, 790.